PL2600865T3 - Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek - Google Patents
Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związekInfo
- Publication number
- PL2600865T3 PL2600865T3 PL11736401T PL11736401T PL2600865T3 PL 2600865 T3 PL2600865 T3 PL 2600865T3 PL 11736401 T PL11736401 T PL 11736401T PL 11736401 T PL11736401 T PL 11736401T PL 2600865 T3 PL2600865 T3 PL 2600865T3
- Authority
- PL
- Poland
- Prior art keywords
- compound
- nonsense
- mutation
- treatment
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 108020004485 Nonsense Codon Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000037434 nonsense mutation Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1056472 | 2010-08-05 | ||
| EP11736401.8A EP2600865B1 (en) | 2010-08-05 | 2011-07-29 | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| PCT/EP2011/063126 WO2012016930A1 (en) | 2010-08-05 | 2011-07-29 | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2600865T3 true PL2600865T3 (pl) | 2019-05-31 |
Family
ID=43447136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11736401T PL2600865T3 (pl) | 2010-08-05 | 2011-07-29 | Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9913829B2 (pl) |
| EP (1) | EP2600865B1 (pl) |
| JP (1) | JP5877200B2 (pl) |
| CN (1) | CN103189060A (pl) |
| CA (1) | CA2806825C (pl) |
| DK (1) | DK2600865T3 (pl) |
| ES (1) | ES2710854T3 (pl) |
| IL (1) | IL224544B (pl) |
| PL (1) | PL2600865T3 (pl) |
| WO (1) | WO2012016930A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2659763T3 (es) | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
| PE20151062A1 (es) * | 2012-12-13 | 2015-08-05 | Novartis Ag | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO |
| BR112015015075A2 (pt) | 2012-12-24 | 2019-01-15 | Univ Ramot | agentes para tratar doenças genéticas resultantes de mutações sem sentido e métodos para identificar as mesmas. |
| WO2014179734A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| WO2015119624A1 (en) * | 2014-02-07 | 2015-08-13 | The Regents Of The University Of Michigan | COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS |
| CU24438B1 (es) | 2014-06-03 | 2019-09-04 | Novartis Ag | Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido |
| US9884862B2 (en) | 2014-06-03 | 2018-02-06 | Novartis Ag | Pyridopyrimidinedione derivatives |
| US9896448B2 (en) | 2014-06-03 | 2018-02-20 | Novartis Ag | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives |
| AR100771A1 (es) * | 2014-06-06 | 2016-11-02 | Ptc Therapeutics Inc | Métodos de tratamiento que utilizan el ácido 1,2,4-oxadiazolbenzoico |
| WO2015198329A1 (en) | 2014-06-25 | 2015-12-30 | Bio Blast Pharma Ltd. | Injectable formulations for intrathecal administration of antibiotic agents |
| WO2016073545A1 (en) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| CN104450727A (zh) * | 2014-11-13 | 2015-03-25 | 深圳华大基因科技有限公司 | X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用 |
| KR20180081516A (ko) * | 2015-10-30 | 2018-07-16 | 피티씨 테라퓨틱스, 인크. | 간질 치료 방법 |
| CA3048193A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
| WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| FR3057776A1 (fr) | 2016-10-21 | 2018-04-27 | Museum National D'histoire Naturelle | Lepista flaccida destine a etre utilise dans le traitement d'une maladie due a une mutation non-sens |
| FR3057774B1 (fr) | 2016-10-21 | 2025-11-07 | Museum Nat Dhistoire Naturelle | Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens |
| JP2020525434A (ja) * | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| CN109200053A (zh) * | 2018-11-17 | 2019-01-15 | 王海玲 | 一种抗癫痫外用药物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3178816A1 (en) * | 2003-04-11 | 2017-06-14 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| JP5800451B2 (ja) * | 2005-04-08 | 2015-10-28 | ピーティーシー セラピューティクス，インコーポレーテッド | ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物 |
| US7772255B2 (en) | 2005-12-13 | 2010-08-10 | Supratek Pharma, Inc. | Method of treating tumors with azaxanthones |
| WO2008021210A2 (en) | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| EP2175845A2 (en) * | 2007-07-11 | 2010-04-21 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
| US20100009934A1 (en) | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| US20120065165A1 (en) * | 2008-10-31 | 2012-03-15 | Arginetix, Inc | Compositions and methods of treating endothelial disorders |
| JP2012528844A (ja) * | 2009-06-01 | 2012-11-15 | バイオコピア リミテッド | 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用 |
-
2011
- 2011-07-29 EP EP11736401.8A patent/EP2600865B1/en not_active Not-in-force
- 2011-07-29 JP JP2013522217A patent/JP5877200B2/ja not_active Expired - Fee Related
- 2011-07-29 WO PCT/EP2011/063126 patent/WO2012016930A1/en not_active Ceased
- 2011-07-29 PL PL11736401T patent/PL2600865T3/pl unknown
- 2011-07-29 ES ES11736401T patent/ES2710854T3/es active Active
- 2011-07-29 CA CA2806825A patent/CA2806825C/en not_active Expired - Fee Related
- 2011-07-29 CN CN2011800479171A patent/CN103189060A/zh active Pending
- 2011-07-29 DK DK11736401.8T patent/DK2600865T3/en active
- 2011-07-29 US US13/813,914 patent/US9913829B2/en active Active
-
2013
- 2013-02-03 IL IL224544A patent/IL224544B/en active IP Right Grant
-
2018
- 2018-01-29 US US15/882,548 patent/US10265302B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL224544B (en) | 2018-07-31 |
| CN103189060A (zh) | 2013-07-03 |
| CA2806825C (en) | 2018-08-21 |
| ES2710854T3 (es) | 2019-04-29 |
| EP2600865A1 (en) | 2013-06-12 |
| US9913829B2 (en) | 2018-03-13 |
| US10265302B2 (en) | 2019-04-23 |
| WO2012016930A1 (en) | 2012-02-09 |
| US20180147191A1 (en) | 2018-05-31 |
| CA2806825A1 (en) | 2012-02-09 |
| US20130217717A1 (en) | 2013-08-22 |
| EP2600865B1 (en) | 2018-11-14 |
| JP2013535479A (ja) | 2013-09-12 |
| JP5877200B2 (ja) | 2016-03-02 |
| DK2600865T3 (en) | 2019-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| LT3378862T (lt) | Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| GB2503066B (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| PT2925757T (pt) | Compostos e composições para o tratamento de doenças parasitárias | |
| IL251083A0 (en) | Compounds and preparations for the treatment of cancer | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| ZA201208646B (en) | Pharmaceutical combination for the treatment of pain | |
| PT2621520E (pt) | Composições de colagenase g e colagenase h para o tratamento de doenças que envolvem alterações de colagénio | |
| IL225793A0 (en) | Methods and preparations for curing insulin-related medical conditions | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| HUE039724T2 (hu) | Injekciós gyógyszerészeti készítmények ízületek kezeléséhez | |
| IL200753A (en) | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis | |
| EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
| PL2460509T3 (pl) | Kompozycja do leczenia brodawek | |
| EP2402342A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | |
| EP2480099A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES | |
| EP2529728A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer | |
| HU0800083D0 (en) | Pharmaceutical compositions for the treatment and prevention of tumorous diseases | |
| HK1178164A (en) | Compositions and methods for the treatment of degenerative diseases | |
| HK1178075A (en) | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |